临床和实验医学杂志
臨床和實驗醫學雜誌
림상화실험의학잡지
JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
2014年
24期
2053-2055
,共3页
转移性乳腺癌%HER-2阳性%赫赛汀%多西他赛
轉移性乳腺癌%HER-2暘性%赫賽汀%多西他賽
전이성유선암%HER-2양성%혁새정%다서타새
Metastatic breast cancer%HER-2 positive%Herceptin%Docetaxel
目的：分析赫赛汀与多西他赛联合应用治疗人类表皮生长因子受体-2（ HER-2）过表达的转移性乳腺癌的临床疗效。方法随机选取2011年1月至2013年12月期间收治的39例HER-2阳性的转移性乳腺癌患者，分成观察组和对照组。观察组给予赫赛汀联合多西他赛方案化疗，对照组给予赫赛汀联合长春瑞滨方案化疗。观察对比两组临床疗效及不良反应。结果观察组总有效为21例（78.8％），患者临床受益为23例（85.2％）；对照组总有效为5例（41.7％），患者临床受益为7例（58.3％）。观察组总有效率显著优于对照组，差异具有统计学意义（ P ＜0.05）；两组临床受益率对比，差异无统计学意义（ P ＞0.05）。两组患者临床不良反应均不明显，主要不良反应表现为发热、皮疹、骨髓抑制以及胃肠道不适。结论赫赛汀与多西他赛联合应用治疗HER-2阳性转移性乳腺癌具有良好的临床疗效及安全性，值得临床推广应用。
目的：分析赫賽汀與多西他賽聯閤應用治療人類錶皮生長因子受體-2（ HER-2）過錶達的轉移性乳腺癌的臨床療效。方法隨機選取2011年1月至2013年12月期間收治的39例HER-2暘性的轉移性乳腺癌患者，分成觀察組和對照組。觀察組給予赫賽汀聯閤多西他賽方案化療，對照組給予赫賽汀聯閤長春瑞濱方案化療。觀察對比兩組臨床療效及不良反應。結果觀察組總有效為21例（78.8％），患者臨床受益為23例（85.2％）；對照組總有效為5例（41.7％），患者臨床受益為7例（58.3％）。觀察組總有效率顯著優于對照組，差異具有統計學意義（ P ＜0.05）；兩組臨床受益率對比，差異無統計學意義（ P ＞0.05）。兩組患者臨床不良反應均不明顯，主要不良反應錶現為髮熱、皮疹、骨髓抑製以及胃腸道不適。結論赫賽汀與多西他賽聯閤應用治療HER-2暘性轉移性乳腺癌具有良好的臨床療效及安全性，值得臨床推廣應用。
목적：분석혁새정여다서타새연합응용치료인류표피생장인자수체-2（ HER-2）과표체적전이성유선암적림상료효。방법수궤선취2011년1월지2013년12월기간수치적39례HER-2양성적전이성유선암환자，분성관찰조화대조조。관찰조급여혁새정연합다서타새방안화료，대조조급여혁새정연합장춘서빈방안화료。관찰대비량조림상료효급불량반응。결과관찰조총유효위21례（78.8％），환자림상수익위23례（85.2％）；대조조총유효위5례（41.7％），환자림상수익위7례（58.3％）。관찰조총유효솔현저우우대조조，차이구유통계학의의（ P ＜0.05）；량조림상수익솔대비，차이무통계학의의（ P ＞0.05）。량조환자림상불량반응균불명현，주요불량반응표현위발열、피진、골수억제이급위장도불괄。결론혁새정여다서타새연합응용치료HER-2양성전이성유선암구유량호적림상료효급안전성，치득림상추엄응용。
Objective To analyse the clinical effect of herceptin in combination with docetaxel in treating patients with HER-2 positive metastatic breast cancer. Methods 39 cases of HER-2-positive metastatic breast cancer form January 2011 to December 2013 were randomly divided into observation group and control group. The observation group was treated with herceptin combination with docetaxel. The control group was treated with herceptin combination with vinorelbine chemotherapy. The clinical efficacy and adverse reactions were observed and compared be-tween two groups. Results The total effective rate was 78. 8%,patients with clinical benefit rate was 85. 2% in the observation group;which was 41. 7% and 58. 3% in the control group. The total efficiency in observation group was significantly better than in the control group( P <0. 05). There was no significant differences in clinical benefit rate( P >0. 05). Patients were not clinically significant adverse reactions,the main adverse reactions manifested as fever,rash,bone marrow suppression and gastrointestinal discomfort. Conclusion Therapy of herceptin in combination with docetaxel in treating patients with HER-2 positive metastatic breast cancer have good clinical efficacy and safety. It is worthy of wider promo-tion.
